National Health Data Infrastructures and Predictive Analytics: A New Asset Class for Investors
1. Introduction: From Individual Tools to Population-Scale Infrastructure
The dominant commercial narrative in digital health has been product-centric: an AI tool that reads a scan, a platform that manages chronic conditions, an app that improves medication adherence. These products matter — but they operate on a substrate that until recently received far less investor attention: the data infrastructure that makes population-scale analytics possible.
That is changing. National health data infrastructures — government-mandated interoperability frameworks, federated data networks, national registries, and FHIR-native data lakes — are emerging as a distinct asset class attracting dedicated investment from sovereign wealth funds, infrastructure-focused PE firms, and strategic health system acquirers.
The thesis is straightforward: whoever controls the infrastructure through which health data flows at national or regional scale holds a structural position in the digital health economy that individual application companies cannot easily replicate or circumvent.
2. The Policy Foundation: Why 2025–2026 Is a Structural Inflection
Several converging policy developments have created the conditions for health data infrastructure investment at scale:
US: TEFCA and FHIR Mandates
The Trusted Exchange Framework and Common Agreement (TEFCA), now operationally active with multiple Qualified Health Information Networks (QHINs), represents the US government’s commitment to nationwide health data interoperability. Combined with the CMS mandated FHIR API requirements for payers and providers, TEFCA creates a standardized data exchange layer upon which analytics infrastructure can be built.
The practical implication: health systems that have achieved FHIR compliance and TEFCA connectivity are generating standardized, queryable patient data at scale — the foundational input for population-level predictive analytics.
EU: European Health Data Space (EHDS)
The European Health Data Space regulation, adopted in 2024, establishes a framework for cross-border health data access for research, policy, and innovation purposes. This creates, for the first time, a legal basis for accessing and analyzing health data across EU member states — a potential dataset of 450 million patients for validated research and commercial AI development.
For investors and founders, the EHDS represents both a regulatory compliance challenge and a commercial opportunity: companies that build compliant data access and analytics infrastructure for EHDS are positioning for a 10-year infrastructure role in European digital health.
Australia, Canada, and UK: National Registry Expansion
Multiple English-speaking healthcare systems have materially expanded their national health registries and federated data networks in 2024–2025. The UK’s NHS Federated Data Platform, built in partnership with Palantir, represents the first major national deployment of a commercial analytics platform on a national health dataset — a precedent-setting model that other health systems are studying.
3. The Asset Class: What Health Data Infrastructure Investment Looks Like
Health data infrastructure as an investment category includes several distinct types of entities:
FHIR-Native Data Platforms
Companies building the technical infrastructure for FHIR-compliant data ingestion, normalization, and analytics. These companies serve health systems, payers, and government health agencies — not patients directly. Their competitive moat is technical depth (handling the extraordinary messiness of real-world EHR data across diverse systems) and the network effect of multi-institution data aggregation.
Examples of the commercial model: SaaS contracts with health systems for data platform licensing, analytics-as-a-service revenue from AI companies that build on the platform, and data access fees from academic research institutions. Revenue is recurring, high-retention, and not dependent on individual clinical outcomes.
Disease-Specific National Registries
Organizations that maintain longitudinal, validated datasets for specific conditions — oncology, cardiology, rare diseases, genomics. These registries represent years or decades of curated clinical data and are the training sets upon which the highest-performing clinical AI models are built.
Investment thesis: registry organizations with deep domain expertise and exclusive data relationships are acquisition targets for large pharma (for drug development), large diagnostic companies (for AI training), and health systems (for population health analytics). Several oncology registry organizations have completed acquisitions at significant premiums in 2023–2025.
Federated Learning Infrastructure
Companies providing the technical frameworks that enable AI model training across distributed datasets without centralizing patient data — addressing the privacy and governance barriers to multi-site AI development. Federated learning infrastructure is increasingly mandatory for companies seeking to train AI models on national-scale datasets without triggering data protection violations.
The FDA’s December 2025 RWE guidance explicitly enables the use of de-identified distributed datasets in regulatory submissions, materially increasing the commercial value of federated learning infrastructure companies.
Health Data Marketplaces
Platforms that enable compliant exchange of de-identified health data between data holders (health systems, payers, labs) and data users (AI companies, pharma, insurance actuaries, academic researchers). These platforms manage the consent, governance, and technical infrastructure for data transactions — a complex regulatory and technical challenge that creates significant defensibility.
4. The Predictive Analytics Layer: From Data to Decision
The commercial value of health data infrastructure is realized through the predictive analytics layer built on top of it. Population-scale data enables categories of analytics that are impossible with single-institution datasets:
Population Risk Stratification
Identifying high-risk patients across a regional or national population — before they present with acute conditions — enables proactive intervention at scale. Health systems and payers using national-scale risk stratification models are demonstrating reduction in preventable hospitalizations and associated costs that generate direct P&L impact.
Key example: CMS’s ongoing investment in population-level risk stratification for its Medicare Advantage and ACO programs has created a large and growing market for companies that can build accurate, nationally validated risk models.
Drug Safety Surveillance
Post-market drug surveillance — monitoring for adverse events, drug interactions, and rare safety signals across the full prescribing population — is a regulatory requirement for pharmaceutical companies and a significant commercial opportunity. Companies with access to national prescription and outcomes datasets are building surveillance platforms that enable faster safety signal detection than traditional pharmacovigilance approaches.
Health System Performance Benchmarking
National datasets enable comparative performance analytics across health systems — identifying institutions whose patient outcomes, procedure rates, and cost profiles diverge from national norms. These insights are valuable to payers, regulators, and health system leadership — creating a market for performance analytics products built on national health data infrastructure.
5. Investment Dynamics: Who Is Entering This Category
Sovereign Wealth and Infrastructure Funds
The long-term, recurring revenue characteristics of health data infrastructure — combined with the strategic national importance of the assets — have attracted sovereign wealth funds and infrastructure-focused investors who are comfortable with longer investment horizons than traditional venture capital. Several national health data platforms in Europe and Asia-Pacific have received significant infrastructure fund investment in 2024–2025.
Healthcare-Focused PE
Private equity firms with healthcare IT expertise are acquiring FHIR platform companies and health data service providers at revenue multiples that reflect the recurring revenue quality and network effect defensibility of these businesses. The typical acquisition multiple for health data infrastructure companies with demonstrated multi-system deployment is in the range of 6–10x ARR, reflecting the strategic value premium.
Strategic Acquirers: Large Health IT and EHR Vendors
Epic, Oracle Health (formerly Cerner), and Veeva are all expanding their data platform capabilities through acquisition and organic development. For founders building health data infrastructure, strategic acquisition by a major EHR vendor represents a natural exit path — one that has been realized multiple times in the past 24 months.
AI Application Companies
Paradoxically, the most sophisticated AI application companies (in imaging, clinical decision support, drug discovery) are investing in upstream data infrastructure as a strategic necessity — recognizing that exclusive access to high-quality training data is a more durable competitive advantage than algorithmic innovation alone.
6. Valuation Framework for Health Data Infrastructure
Investors evaluating health data infrastructure companies use a distinct set of metrics from those applied to clinical AI application companies:
| Metric | Description | Benchmark |
|---|---|---|
| Data breadth | Number of patients represented in the platform | >1M for regional; >10M for national-scale |
| Data depth | Years of longitudinal follow-up per patient | >5 years preferred |
| Institution count | Health systems or payers contributing data | >20 for platform credibility |
| API call volume | Monthly queries from external users/AI companies | Growth rate proxy |
| Revenue per institution | Annual contract value per health system customer | $200K–$2M depending on scope |
| Compliance certifications | HIPAA, SOC2, ISO 27001, GDPR/EHDS alignment | All required for institutional customers |
7. Risks and Mitigants
Data Governance Complexity
National health data infrastructure sits at the intersection of privacy law, healthcare regulation, and competitive commercial dynamics. The consent frameworks, data use agreements, and institutional governance processes required to maintain compliant access to national-scale datasets are operationally complex and expensive.
Mitigant: companies that have built compliance infrastructure proactively — and can demonstrate clean audits and clear data provenance — command significant premium over those still navigating governance uncertainty.
Policy Dependency
Infrastructure companies whose business models depend on government-mandated interoperability standards are exposed to policy risk — changes in administration, regulatory priorities, or healthcare reform can alter the regulatory landscape. The US experience with meaningful use incentives (which drove EHR adoption but then plateaued in impact) is an instructive historical precedent.
Mitigant: diversification across multiple national markets (US, EU, UK, Australia) reduces single-market policy risk exposure.
Data Quality Variability
The quality of health data generated by clinical systems is highly variable — driven by documentation habits, coding practices, system configurations, and patient population characteristics. Platforms that invest in data quality curation, normalization, and validation are building a more valuable and more defensible asset than those that aggregate raw data without quality management.
8. Conclusion: Infrastructure as the Durable Advantage
The history of technology platform industries consistently demonstrates a pattern: infrastructure companies outperform application companies over long investment horizons. The companies that built cloud infrastructure outperformed most applications built on that infrastructure. The companies that built mobile network infrastructure outperformed most mobile apps.
Health data infrastructure is following this pattern. The FHIR platforms, federated learning networks, national registries, and health data marketplaces that are being built in 2025–2026 will form the foundational layer of digital health for the next decade. The analytics products, AI applications, and precision medicine tools that drive the most visible investment headlines will run on this infrastructure.
For investors with appropriate time horizons and capital structures, health data infrastructure represents one of the most structurally durable investment opportunities in digital health — less visible than clinical AI applications, but more foundational, more defensible, and more likely to generate compounding returns.
Sources: FDA RWE Final Guidance 2025 · IQVIA FDA RWE Update January 2026 · Sprypt FHIR Guide 2025 · McKinsey Health Analytics · Clindcast FHIR Vendors 2025